Literature DB >> 21523561

The role of lymph node dissection in renal cell carcinoma.

Brian F Chapin1, Scott E Delacroix, Christopher G Wood.   

Abstract

Due to the relatively heterogeneous metastatic spread of renal cell carcinoma (RCC) through both hematogenous and lymphatogenous routes, the surgical extirpation of regional lymph nodes in the treatment of RCC has long been a controversial topic. Individual risk is dependent on multiple variables including tumor stage, grade, and histologic sub-type, in addition to many others. Controversy exists over whether lymph node dissection (LND) simply provides improved staging or whether removal of pathologic nodes offers a therapeutic advantage. Herein, we evaluate the available data regarding the use of LND in the treatment of RCC. While we believe that LND may provide an opportunity for cure in a select group of patients, there are many variables to consider when determining its applicability to an individual patient.

Entities:  

Mesh:

Year:  2011        PMID: 21523561     DOI: 10.1007/s10147-011-0241-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  36 in total

1.  Intrapulmonary lymph node metastasis and renal cell carcinoma.

Authors:  Jalal Assouad; Marc Riquet; Pascal Berna; Claire Danel
Journal:  Eur J Cardiothorac Surg       Date:  2006-11-21       Impact factor: 4.191

2.  Renal lymphatic drainage and thoracic duct connections: implications for cancer spread.

Authors:  J Assouad; M Riquet; C Foucault; G Hidden; V Delmas
Journal:  Lymphology       Date:  2006-03       Impact factor: 1.286

3.  Reassessment of renal cell carcinoma lymph node staging: analysis of patterns of progression.

Authors:  Taekmin Kwon; Cheryn Song; Jun Hyuk Hong; Choung-Soo Kim; Hanjong Ahn
Journal:  Urology       Date:  2011-02       Impact factor: 2.649

4.  Feasibility of sentinel node detection in renal cell carcinoma: a pilot study.

Authors:  Axel Bex; Lenka Vermeeren; Geraldine de Windt; Warner Prevoo; Simon Horenblas; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-29       Impact factor: 9.236

5.  Reassessing the current TNM lymph node staging for renal cell carcinoma.

Authors:  Carlo Terrone; C Cracco; F Porpiglia; E Bollito; C Scoffone; M Poggio; A Berruti; F Ragni; M Cossu; R M Scarpa; S Rocca Rossetti
Journal:  Eur Urol       Date:  2005-12-20       Impact factor: 20.096

6.  A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma.

Authors:  Michael L Blute; Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

7.  Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.

Authors:  Allan J Pantuck; Amnon Zisman; Frederich Dorey; Debby H Chao; Ken-Ryu Han; Jonathan Said; Barbara Gitlitz; Arie S Belldegrun; Robert A Figlin
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

8.  The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.

Authors:  John F Ward; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

9.  Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective.

Authors:  Giovanni Lughezzani; Umberto Capitanio; Claudio Jeldres; Hendrik Isbarn; Shahrokh F Shariat; Philippe Arjane; Hugues Widmer; Paul Perrotte; Francesco Montorsi; Pierre I Karakiewicz
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

10.  Value of frozen section analysis of enlarged lymph nodes during radical nephrectomy for renal cell carcinoma.

Authors:  Xia Ming; Lin Ningshu; Li Hanzhong; Huang Zhongming; Liu Tonghua
Journal:  Urology       Date:  2009-04-10       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.